Cargando…
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107664/ https://www.ncbi.nlm.nih.gov/pubmed/30139993 http://dx.doi.org/10.1038/s41598-018-31027-y |
_version_ | 1783350003982401536 |
---|---|
author | Zhong, Qi Fang, Jugao Huang, Zhigang Yang, Yifan Lian, Meng Liu, Honggang Zhang, Yixiang Ye, Junhui Hui, Xinjie Wang, Yejun Ying, Ying Zhang, Qing Cheng, Yingduan |
author_facet | Zhong, Qi Fang, Jugao Huang, Zhigang Yang, Yifan Lian, Meng Liu, Honggang Zhang, Yixiang Ye, Junhui Hui, Xinjie Wang, Yejun Ying, Ying Zhang, Qing Cheng, Yingduan |
author_sort | Zhong, Qi |
collection | PubMed |
description | Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients. |
format | Online Article Text |
id | pubmed-6107664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61076642018-08-28 A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma Zhong, Qi Fang, Jugao Huang, Zhigang Yang, Yifan Lian, Meng Liu, Honggang Zhang, Yixiang Ye, Junhui Hui, Xinjie Wang, Yejun Ying, Ying Zhang, Qing Cheng, Yingduan Sci Rep Article Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients. Nature Publishing Group UK 2018-08-23 /pmc/articles/PMC6107664/ /pubmed/30139993 http://dx.doi.org/10.1038/s41598-018-31027-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Zhong, Qi Fang, Jugao Huang, Zhigang Yang, Yifan Lian, Meng Liu, Honggang Zhang, Yixiang Ye, Junhui Hui, Xinjie Wang, Yejun Ying, Ying Zhang, Qing Cheng, Yingduan A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title | A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title_full | A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title_fullStr | A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title_full_unstemmed | A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title_short | A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
title_sort | response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107664/ https://www.ncbi.nlm.nih.gov/pubmed/30139993 http://dx.doi.org/10.1038/s41598-018-31027-y |
work_keys_str_mv | AT zhongqi aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT fangjugao aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT huangzhigang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yangyifan aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT lianmeng aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT liuhonggang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhangyixiang aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yejunhui aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT huixinjie aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT wangyejun aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingying aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhangqing aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT chengyingduan aresponsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhongqi responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT fangjugao responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT huangzhigang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yangyifan responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT lianmeng responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT liuhonggang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhangyixiang responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yejunhui responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT huixinjie responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT wangyejun responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT yingying responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT zhangqing responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma AT chengyingduan responsepredictionmodelfortaxanecisplatinand5fluorouracilchemotherapyinhypopharyngealcarcinoma |